Astrid Murumägi

Precision Systems Medicine
äldre forskare, Institutet för molekylärmedicin i Finland

Telefon+358504151680, +358294125765
E-postadressastrid.murumagi@helsinki.fi

PL 20 (Tukholmankatu 8)
00014
Finland

Forskningsoutput per år

Om du gjort några ändringar i Pure kommer de visas här snart.

Personlig profil

Forskningsintressen

Astrid Murumägi is a senior scientist at the Kallioniemi group. She received her PhD in Molecular Immunology at the University of Tampere. During her postdoctoral training she transitioned to systems biology and genomics by joining Prof. Olli Kallioniemi´s team at FIMM in 2009. Her work is focused on applying systems medicine in cancer research. She is involved in the FIMM Grand Challenge on Individualized Systems Medicine program. More specifically, she is responsible for ovarian cancer and melanoma functional precision medicine projects, where patient-derived cancer cells are used for comprehensive drug sensitivity testing and molecular profiling to identify best treatment strategies for patients. In addition she is involved in several collaboration projects where the drug testing platform has been applied to uncover novel drug vulnerabilities in cancer cells.

Vetenskapsgrenar

3111 Biomedicinska vetenskaper
318 Medicinsk bioteknologi
3122 Cancersjukdomar

Internationellt och inhemskt samarbete Publikationer och projekt inom de senaste fem åren.

Publikationer

26 Artikel
7 Mötesabstrakt
1 Brev
1 Översiktsartikel

Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness

Karvonen, H., Arjama, M., Kaleva, L., Niininen, W., Barker, H., Koivisto-Korander, R., Tapper, J., Pakarinen, P., Lassus, H., Loukovaara, M., Bützow, R., Kallioniemi, O., Murumägi, A. & Ungureanu, D., 23 sep 2020, I : Cell Death and Disease. 11, 9, 12 s., 790.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Öppen tillgång

Fil

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Malani, D., Yadav, B., Kumar, A., Potdar, S., Kontro, M., Kankainen, M., Javarappa, K. K., Porkka, K., Wolf, M., Aittokallio, T., Wennerberg, K., Heckman, C. A., Murumägi, A. & Kallioniemi, O., okt 2020, I : Leukemia. 34, 10, s. 2780-2784 3 s.

Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig › Peer review

Anagrelide for Gastrointestinal Stromal Tumor

Pulkka, O-P., Gebreyohannes, Y. K., Wozniak, A., Mpindi, J-P., Tynninen, O., Icay, K., Cervera, A., Keskitalo, S., Murumägi, A., Kulesskiy, E., Laaksonen, M., Wennerberg, K., Varjosalo, M., Laakkonen, P., Lehtonen, R., Hautaniemi, S., Kallioniemi, O., Schöffski, P., Sihto, H. & Joensuu, H., 1 mar 2019, I : Clinical Cancer Research. 25, 5, s. 1676-1687 12 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

Murumagi, A., Ungureanu, D., Khan, S., Hirasawa, A., Arjama, M., Valimaki, K., Mikkonen, P., Niininen, W., Kumar, A., Eldfors, S., Pellinen, T., Pietiainen, V., Magi, A., Koivisto-Korander, R., Tapper, J., Loukovaara, M., Aittokallio, T., Butzow, R. & Kallioniemi, O., jul 2019, I : Cancer Research. 79, 13, 2 s.

Forskningsoutput: Tidskriftsbidrag › Mötesabstrakt › Forskning › Peer review

Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting

Karvonen, H., Perttila, R., Niininen, W., Hautanen, V., Barker, H., Murumagi, A., Heckman, C. A. & Ungureanu, D., 25 apr 2019, I : Oncogene. 38, 17, s. 3288-3300 13 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review